The board of directors (the "Board") of CSPC Pharmaceutical Group Limited announce that the Roxadustat Capsules (20mg/50mg) (the "Product") developed by the Group has obtained drug registration approval granted by the National Medical Products Administration of the People's Republic of China. The Product is the first generic drug of its kind that has been approved in China, and is deemed to have passed the consistency evaluation of quality and efficacy for generic drugs. Roxadustat is the world's first hypoxia-inducible factor-prolyl hydroxylase inhibitor (HIF-PHI), which is suitable for anemia caused by chronic kidney disease (CKD) in patients receiving dialysis and non-dialysis treatment.

As a new generation oral drug for the treatment of renal anemia with novel mechanism, Roxadustat corrects anemia by activating the HIF pathway that promotes endogenous erythropoietin (EPO) production, reduces the hepcidin levels, and improves iron absorption, transport and utilisation. Roxadustat received the highest level (Level 1A) ofrecommendation in the Clinical Practice Guidelines for the Diagnosis and Treatment of Renal Anemia in China and the Chinese Expert Consensus on the Treatment of Renal Anemia with Roxadustat.